Company profile
Insulet Corp.
NASDAQ: PODD · Healthcare · Medical - Devices
PublicHQ Acton, MACIK 0001145197Reports USD
#97 of 1,418 Healthcare companies by revenue72nd-percentile growth
EA Score
83B+FH 85DQ 83GM 74SS 87
v0.1 · 65/100 weight · provisional
↑ market scale, Piotroski F · ↓ balance-sheet leverage, revenue growth (YoY)
Methodology →Revenue TTM
$2.9B
Rev growth YoY (TTM)
+31.9%
Net income (FY)
$247.1M
Employees
5,400
as of 2026-08-06
Market cap
$9.2B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.7B$2.7B2025
Net income$247.1M$247.1M2025
Operating income$473.8M$473.8M2025
Total assets$3.2B$3.2B2025
Liabilities$1.7B$1.7B2025
Equity$1.5B$1.5B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
International Omnipod99%
Drug Delivery1%
By geography
UNITED STATES72%
Non-US28%
The read
What is Insulet Corp.’s revenue?
Insulet Corp. booked $2.7B in FY2025 revenue, growing 31% year over year — faster than most Healthcare companies we track, at a 9.1% net margin.
Peers · Healthcare
QuidelOrtho Corporation54DFortrea Holdings Inc.50DEnvista Holdings Corp73BBio-Rad Laboratories, Inc.84B+Medpace Holdings, Inc.84B+Chemed Corporation89AKey facts
CEOAshley McEvoy
SectorHealthcare
IndustryMedical - Devices
HeadquartersActon, MA
ExchangeNASDAQ: PODD
Employees5,400
IPO date2007-05-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.